Pfizer and Bristol Myers Squibb Face Patent Cliff Declines

Pfizer and Bristol Myers Squibb Company are managing significant financial challenges as they approach patent cliffs, a cycle where expiring protections trigger steep revenue drops. This trend has led to substantial stock declines, with Pfizer's shares falling 55% from 2021 highs and Bristol Myers Squibb Company's decreasing 35% from its 2022 peak.

To recover competitiveness and expand its GLP-1 weight loss drug pipeline, Pfizer has pursued an acquisition and signed a licensing agreement with a Chinese drugmaker to market a new drug candidate. These moves contrast with the dominant market position of Eli Lilly and Company, which currently maintains a high price-to-earnings ratio in the weight loss sector.

Investors view the two companies as different risk profiles. Bristol Myers Squibb Company is positioned as a safer income option with a 4.8% dividend yield. Pfizer is characterized as a higher-risk turnaround play with a 6.6% dividend yield, though its 100% payout ratio introduces potential dividend risk.